Events

CALIXAR team will be present at the online BIO Asia – Taiwan event, from July 21 to 25, 2021 to discuss about commercial and scientific opportunities linked to our activities. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. CALIXAR wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025. About BIO Asia – Taiwan event Jointly organized by the global Biotechnology Innovation Organization (BIO) and the Taiwan Bio Industry Organization (Taiwan BIO) the BIO Asia – Taiwan International Conference and Exhibition was held for the first time in 2019.  This year BIO Asia – Taiwan 2021 (online), brings together biotechnology and pharmaceutical executives and investors from North America, Europe and Asia to explore business opportunities with Taiwan’s emerging biotech sector with a unique format of online and live settings. For more information and meet us: BIO Asia – Taiwan

CALIXAR team will be present at the online 9th Antibody Industrial Symposium 2021, from June 22 to 25, 2021 to discuss about commercial and scientific opportunities linked to our activities. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. The biotech company wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025. About 9th Antibody Industrial Symposium The 9th Antibody Industrial Symposium is an international congress jointly organized by the scientific society LabEx MAbImprove and the industrial organization MabDesign. It is part of the series of Industrial Symposia organized by MAbImprove since 2013. The AIS2021 is the ideal conference for scientists, industrials, physicians and policymakers to exchange about therapeutic antibodies and more! The Scientific committee has set up an exciting program, with keynote lectures, pitch talks around new creative projects, and industrial talks from big pharmaceutical companies. For more information and meet us: 9th Antibody Industrial Symposium

CALIXAR team will be present at the online BIO KOREA International Convention event, from June 9 to 21, 2021 to discuss about commercial and scientific opportunities linked to our activities. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. The biotech company wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025. About BIO KOREA International Convention BIO KOREA has been held every year since 2006 and serving as a business platform for international bio companies. This 15th year event brings together various international academics, professionals, and CEOs of global bio companies to obtain, exchange, and discuss diverse affairs, through exhibition, business forum(partnering), and conference. BIO KOREA has been providing abundant opportunities to assure competitive edges within the convergence industry centered around biotechnology. For more information and meet us: BIO KOREA International Convention

CALIXAR team will attend at the online Redefining Early Stage Investments (RESI) event, from June 8 to 10, 2021 to present its new licensing business model and to develop its pipeline of native targets of pharmaceutical interest. CALIXAR is a biotech company specialized in the identification and isolation of functional membrane therapeutic targets and antigens (GPCRs, Ion channels, Transporters, …). The company is currently investing in the extension of its pipeline of highly druggable membrane protein targets and native antigens. Within the next few years, CALIXAR will be able to offer to Pharma companies native and functional therapeutic targets validated and in a ready-to-discovery format. The biotech company wants to become a leader in the early discovery segment of drug development based on complex therapeutic targets (membrane proteins), a market predicted to be worth € 70 bn by 2025. About the Redefining Early Stage Investments (RESI) The Redefining Early Stage Investments (RESI) conference series connect start-ups and early-stage investors and strategic channel partners. The RESI maximizes fundraising companies’ efforts to find partners who are a fit for their technology and stage of development. The RESI is uniquely cross-border and cross-domain, connecting start-ups with 10 categories of global investors across the silos of drugs, devices, diagnostics and digital health (4 Ds). For more information and meet us: Redefining Early Stage Investments (RESI)

CALIXAR team will be present at the online Festival of Biologics USA, from March 29 to April 01, 2021 to meet you and discuss about commercial and scientific issues linked to our activities. CALIXAR is a biotech company specialized in the isolation of native membrane therapeutic targets and antigens. This digital event will be a great opportunity to present CALIXAR’s proprietary technologies and know-how to collaborate with academia and industries in the development of innovative drugs and antibodies. About the Festival of Biologics USA: The Festival of Biologics USA is the meeting place for the life science community to bridge the gap between academia and industry. With three events in one (the Americas Antibody Congress, the World Immunotherapy Congress and the World Immunotherapy Congress), this Festival encourages conversation across the entire industry, to inspire change, champion innovation, and address complex challenges that the biologics industry is facing. For more information and meet us: Festival of Biologics USA

CALIXAR team will participate at the 4th Congress of Immunotherapies & Innovations for Infectious Diseases to meet partners working on this thematic and exchange about strategies and scientific issues tied up on its activities.

CALIXAR team will be present at BIO Europe Digital, the October 26-29, 2020 to meet you and exchange about commercial and scientific issues tied up on our activities.

CALIXAR team will be present at BIO JAPAN 2020 event online, (October 14-16th, 2020) to meet you and exchange about commercial and scientific opportunities tied up on our activities.

CALIXAR team will be present at Biotech & Pharma Virtual Partnering Conference, the 28 to 30 September 2020 to meet you and exchange about commercial and scientific issues tied up on our activities.

CALIXAR team will be present at BIO Digital, the 8-12 June 2020 to meet you and exchange about commercial and scientific issues tied up on our activities.

CALIXAR will present its new funding round that will allow it to expand its licensing business model and develop a pipeline of targets of pharmaceutical interest.

CALIXAR team will attend at Virtual Partnering Event against Covid-19 on 4 to 6 May 2020.

CALIXAR will present its new funding round that will allow it to expand its licensing business model and develop a pipeline of targets of pharmaceutical interest.

CALIXAR will present its new funding round that will allow it to expand its licensing business model and develop a pipeline of targets of pharmaceutical interest.

CALIXAR team will be present at BIO-EUROPE SPRING event at Paris, the 23-25 March 2020 to meet you and exchange about commercial and scientific issues tied up on our activities.

CALIXAR to sponsor the 8th annual meeting of GDR3545-GPCR in Montpellier – France.

CALIXAR selected speaker at the EMBO Workshop: Tools for Structural Biology of Membrane Proteins in Hamburg.

Case study of Potassium chloride co-transporter KCC2;

CALIXAR to attend the 17th Annual Discovery on Target Summit in Boston

CALIXAR as invited speaker at the Immuno-technologies Day in Paris.

CALIXAR to attend the 7th Antibody Industrial Symposium in Tours.

CALIXAR to present at the 14th Annual Drug Discovery Chemistry Conference in San Diego.